NCT07595159CompletedPhase 1
A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B
A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Chinese Healthy Subjects and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity in Chinese Subjects With Chronic HBV Infection
Source: ClinicalTrials.gov · Last updated 31 Jul 2026
Brief summary (registry, in English)
Phase 1 Study of BW-20507 in Healthy Subjects and Patients With Chronic Hepatitis B. Ia involved a single ascending dose study where healthy participants were administered one dose of BW-20507 or placebo subcutaneously. Ib involved a multiple ascending dose study where participants with chronic hepatitis B virus infection were administered with multiple doses of BW-20507 SC
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 29 Mar 2026
- Start date
- 24 Jun 2024
- Primary completion date
- 18 Nov 2025
- Lead sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Diseases
- Hepatitis B
- NCT number
- NCT07595159
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 32
- From 24 Jun 2024 to the primary completion date, 18 Nov 2025
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Significant hepatic fibrosis or hepatic cirrhosis, i.e., FibroScan \>9.0 kPa within 1 month prior to screening, or liver paracentesis pathology showing advanced hepatic fibrosis (Metavir F3) or hepatic cirrhosis (Metavir F4) within 1 year prior to screening
Other illness
- Any other clinically significant chronic liver disorders in addition to chronic HBV infection, including but not limited to: alcoholic liver disease, moderate or above fatty liver, autoimmune liver disease, hereditary metabolic liver disease, etc.
Lab values
- Any clinically significant chronic diseases of cardiovascular, respiratory, endocrine, immune, renal, gastrointestinal, skin, hematologic, neuropsychiatric, or other systems (excluding chronic HBV infection), or laboratory test abnormal (unrelated to chronic HBV infection) that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study
Other
- Ia
- unhealthy male or female participants
Who the study is looking for
- Ia：
- healthy male or female participants Ib：
- Males or females aged 18 to 65 years (inclusive) at the time of informed consent
- Body mass index (BMI) ≥18 and ≤28 kg/m2, with body weight \>50 kg (male) or 45 kg (female)
- Serum hepatitis B surface antigen (HBsAg) positive for ≥6 months at screening
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Argo Investigative Site Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Argo Investigative Site Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
| Argo Investigative Site Coordinator of this site? Confirm its status | Guanzhou | China | Unknown status |
| Argo Investigative Site Coordinator of this site? Confirm its status | Xuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.